Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we ...

I believe that there are no prerequisites for Leonard Schleifer, who is the CEO of Regeneron, to suspend the share buyback program. Over the past four years, Regeneron Pharmaceuticals has ...

CEO Leonard Schleifer highlighted 10% revenue growth ... expressed increased concerns about competitive pressures on EYLEA. Regeneron capped 2024 with strong revenue growth and significant ...

There is nothing wrong with paying dividends and buying back shares, but in Regeneron's case, management is, apparently, prioritizing the latter. As the company's CEO, Leonard Schleifer ...

Hard on the heels of Regeneron moving its COVID-19 antibody ... use authorization is granted,” said Regeneron’s CEO Leonard Schleifer. “This manufacturing and supply agreement with BARDA ...

Biotech company Regeneron (NASDAQ ... dividend program and increased share repurchase capacity," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer ...